Offination Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number	10570849			
INFORMATION BIOOL COURS	Filing Date	2006-03-06			
INFORMATION DISCLOSURE	First Named Inventor Jamai Tazi				
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit	ox	1794 1628		
(Not for Submission under or of K 1.33)	Examiner Name	~ M⊚t ~¥	-Not-Vet-Assigned		Shiao
	Attorney Docket Number		REGIM 3.3-085		

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document Relevan			s,Columns,Lines where ant Passages or Relevant es Appear		
	1										
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	of cited Document Relev		Releva	s,Columns,Lines where vant Passages or Releval es Appear		
	1										
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² i Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		T5	
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10570849			
Filing Date		2006-03-06			
First Named Inventor	Jama	Tazi			
Art Unit	101	4794	1628		
Examiner Name	Mot-W	ct-Assigned	R.T.	Shiao	
Attorney Docket Numb	er	REGIM 3.3-0	85		

1	SHARP, P.A. (1994). Split genes and RNA splicing. Cell 77, 805-815).	
2	MANLEY, J.L. AND TACKE, R. (1996). SR proteins and splicing control. Genes Dev. 10, 1569-1579.	
3	GRAVELEY, B.R. Sorting out the complexity of SR protein functions. RNA.2000. 6, 1197-1211.	
4	WANG, H.Y. et al., SC35 plays a role in T cell development and alternative splicing of CD45. Mol.Cell 2001. 7, 331-342.	
5	EWING, B. AND GREEN, P. Analysis of expressed sequence tags indicates 35,000 human genes. Nat.Genet.2000. 25, 232-234.	
6	CARTEGNI, L. et al., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat.Rev. Genet.2002. 3, 285-298.	
7	NISSIM-RAFINIA, M. et al., Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum.Mol.Genet.2000. 9, 1771-1778;	
8	SAZANI, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol.2002. 20, 1228-1233.	
9	CARTEGNI, L. et al., Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat.Struct. Biol.2003. 10, 120-125.	
10	ANDREASSI, C. et al., Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum.Mol.Genet.2001.10, 2841-2849.	
11	LIU, X et al., Partial correction of endogenous DeltaF508 CFTR in human cystic . fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat.Biotechnol. 2002. 20, 47-52.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10570849				
Filing Date		2006-03	-06			
First Named Inventor	Jama	Tazi				
Art Unit		7794	1628			
Examiner Name	₩ 	et-Ascign	ed .	R.T.	Shiao	
Attorney Docket Number		REGIM:	3.3-085			

	12	JEKAMA, K. et al., Cyclodextrins in drug carrier systems. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 1-40.						
	13	PROCHIANTZ, A., Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr.Opin.Neurobiol. 1996. 6, 629-634						
	14	et VIVES, E. et al., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J.Biol.Chem. 1997. 272, 16010-16017.						
	15	DOUGLAS, S.J. et al., Nanoparticles in drug delivery. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 233-261 Gregoriadis, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.						
	16	BLACK, D.L., Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu.Rev.Biochem.2003. 72,291-336.						
	GREGORIADIS, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.							
If you wis	n to ac	additional non-patent literature document citation information please click the Add button Add	-					
		EXAMINER SIGNATURE						
Examiner	Signa	re /Rei Tsang Shiao/ Date Considered 10/21/10						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								